GlassScriptPhysician profile
Christopher R Lynch
NPI 1568402683
$14,474.98
in general payments reported to CMS, 2019-2025
68 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,486 · 2020: $2,227 · 2021: $2,395 · 2022: $1,539 · 2023: $2,260 · 2024: $2,020 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,785 · Education: $28.52 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.73 |
| Education | $28.52 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,423.03 | 2019-2025 | |
| Novo Nordisk INC | $1,653.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,220.38 | 2019-2024 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,116.30 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $984.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.36 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $729.12 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $633.33 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $625.25 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $390.00 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $359.60 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $253.16 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.82 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $202.09 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.65 | 2019-2023 | Xifaxan, Ibschek |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.